we have attempted to discover new and better antiarrhythmic drugs by testing drugs with known neurodepressant effects against experimentally induced arrhythmias.4 We have found that chlordiazepoxide is effective in the treatment of ventricular arrhythmias induced by either digitalis or coronary occlusion. Chlordiazepoxide in combination with the peripherally-acting antiarrhythmic agent, lidocaine, is able to enhance the effect of lidocaine on arrhythmias evoked by coronary occlusion.4
677, 1971 4. GILIIs RA, THIBODEALx H, BARR L: Antiarrhythmic properties of chlordiazepoxide. Circulation, in press 5. Nixo.\ PGF, TAYLOR DJE, MORTON SD, BRONIFIELI) M: A sleep regimen for myocardial infarction. Lancet 1: 726, 1968 Propranolol and Oxygen-Hemoglobin Equilibrium
To the Editor:
The article by Lichtman and others (Circulation 49: 881, 1974) entitled "Effect of Propranolol on Oxygen Binding to Hemoglobin in Vitro and in Vivo" was a major step forward in the understanding of the biochemical effects of this drug.
We would disagree, however, with one of the conclusions. The authors state that "Propranolol (10 to 360 mg) administered to human subjects did not affect hemoglobinoxygen affinity.'' This was based on measurement of P50 in six presumably healthy subjects before propranolol, and four and twenty-four hours after administration of forty milligrams or less. The authors found no significant change in P5,. They also measured P50 in two subjects on large doses (180 and 360 mg per day) of propranolol and found it to be "within one standard deviation of their normal mean.'
We have shown that patients with coronary artery disease on chronic oral therapy with propranolol (mean 150 mg per day) for at least three months do have a significantly increased P50 on the drug compared to their P50 off the drug (Am J Cardiol 33: 170, 1974). This demonstrated shift in oxygen affinity could increase systemic oxygen delivery 20-30%G. Perhaps the differences in our data may be explained by differences in duration of drug ingestion. Most patients in Lichtman's paper were studied after only one dose of the drug. The two patients that were on chronic oral therapy, only had measurements while they were on propranolol. No control P50s were done while they were off the drug.
The duration and amount of oral therapy necessary for the in vivo effect of propranolol on P50 is incompletely understood. Manchester and others have shown observable effects on P50 2 hours after 40 mg of propranolol given as 10 mg orally q4h ( The authors reply: To the Editor:
We thank Dr. Sheps and colleagues for calling our attention to their studies and for their comments. Their finding that propranolol results in an increase in P5, after at least three months of treatment is of interest but the abstract by Schrumpf et al. to which they refer does not indicate a direct effect of propranolol on the red cell. Propranolol used in higher doses for long periods may lead to changes in cardiac or pulmonary function which might result in an increase in P50 indirectly. At this time four variables are accepted as capable of producing major alterations in the oxygen-hemoglobin equilibrium: red cell temperature, red cell 2,3diphosphoglycerate (2,3-DPG) concentration, red cell pH and the non-pH related effect of red cell CO2. When P50 is measured at standard conditions, all but 2,3-DPG are normalized. P5o at standard conditions (P50 std), which we assume to have been the variable measured by Schrumpf et al., is usually, therefore, an indirect measure of red cell 2,3-DPG if the red cell contains normal adult hemoglobin. Red cell 2,3-DPG concentration has been correlated most con-vincingly with blood pH and this correlation appears to be causal; alkalosis results in an elevated 2,3-DPG and acidosis results in a decreased 2,3-DPG. Heart failure has been associated with increased red cell 2,3-DPG' as well as increased blood pH;2' 3hence, studies of changes in P50 in patients with cardiac disease using propranolol should inquire as to the role of these additional variables.
Also, the net effect of all factors contributing to the oxygen-hemoglobin equilibrium must be measured before estimates can be made of its effect on oxygen delivery.2'3'4
For example, P50 std (i.e., red cell 2,3-DPG content) when used by itself may be misleading as an index of the position of the oxygen-hemoglobin dissociation curve particularly if the increase in 2,3-DPG is due to alkalosis, since the net result on oxygen binding to hemoglobin may be nil.4
From our experience it appears improbable to us that propranolol has a detectable direct effect on the red cell in doses administered to man. Our studies do not exclude the possibility that protracted, high dose propranolol treatment may affect hemoglobin-oxygen affinity indirectly such as by altering cardiac, pulmonary or renal function. We believe, therefore, that it will be important for these additional factors to be considered before any final conclusions can be drawn about the mechanism or the efficacy of long-term
